VX-222

Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR)
Yahoo/BusinessWire
Sat, 11/5/11 - 02:48 pm
VX-222
Incivek
Vertex Pharmaceuticals
Vertex 4-drug hepatitis C combo shows promise
Reuters
Wed, 07/27/11 - 10:40 am
Vertex Pharmaceuticals
hepatitis C
VX-222
Incivek
pegylated interferon
ribaviron
Positive Data for Vertex HCV Drug
Yahoo/Zacks
Sat, 04/2/11 - 10:23 am
Vertex Pharmaceuticals
VX-222
HCV
Vertex Pharmaceuticals' potential hepatitis C treatment meets safety goal in midstage study
Yahoo/AP
Thu, 03/31/11 - 12:27 pm
hepatitis C
Vertex Pharmaceuticals
VX-222